The Global. The Spanish Association of Biosimilar Medicines (BioSim) has presented itself in society this Tuesday at the Ministry of Health. BioSim brings together the companies Accord, Boehringer Ingelheim, Cinfa, Gedeon Richter, Kern Pharma, Lilly, mAbxience, Merck, Mylan, Novartis, Rovi, Sandoz, Sanofi, Stada and Teva, to integrate and join forces for the benefit of biosimilars, some medicines equivalent in terms of quality, efficacy and safety to biotechnological medicines of reference, which will mean savings of around 1.500 million euros for administrations by 2020 and will improve citizens' access to treatment for serious diseases. The ministry estimates, on the other hand, that these savings will oscillate between 300 and 400 million euros per year.